neuroscience

News

Otsuka makes psychedelics play, buying Mindset

Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

R&D

JP Morgan 2023 – Pre event

Before the main event at JP Morgan 2023 even kicks off, we’re checking out the Sachs Associates Neuroscience Innovation Forum on Sunday.

News

Alkermes may separate oncology business, says CEO

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.

Partner Content